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Abstract 
Persistent left superior vena cava (LPSVC) is a rare congenital anomaly of the thoracic venous 
system that can trigger paroxysmal atrial fibrillation (AF). The role of this venous anomaly must 
be carefully considered in patients undergoing conventional AF transcatheter ablation by 
pulmonary vein isolation to avoid unnecessary lesions, left atrium access and arrhythmia 
relapses. In fact, the present clinical perspective suggests sole LPSVC isolation as a safe and 




















Persistent left superior vena cava (LPSVC) results from the patency of the left cardinal vein 
which, rather than undergoing the embryological transformation into the ligament of Marshall, 
remains pervious and drains into a dilated coronary sinus (CS). The incidence of LPSVC has been 
reported between 0.1 and 3% in individuals with normal hearts1,2 and candidates as the most 
common congenital anomaly of the thoracic venous system. In case of the presence of other 
congenital heart defects its prevalence raises to about 3%3. More rarely, in about 0.1% of the 
cases, instead, the presence of LPSVC is associated with the absence of the right SVC4.  
LPSVC usually does not have direct hemodynamic significance: it is usually asymptomatic and 
detected when cardiovascular imaging is performed for concomitant reasons. However LPSVC 
has been identified as a potential trigger for paroxysmal atrial fibrillation (AF)5-6. Hsu et al.5 
suggested that, as a consequence of the unusual embryologic development, the LPSVC might be 
associated to the presence of muscular and pacemaker tissue, explaining the arrhythmogenicity 
originating from this vein.  
Given these presumptions the role of this venous anomaly must be carefully considered in 
patients with paroxysmal AF and LPSVC in order to avoid arrhythmia recurrences in patients 
undergoing conventional AF transcatheter ablation.7  
 
Clinical perspective 
Within more than 700 patients referred to our institution, between January 2010 and January 
2013, for ablation of recurring episodes of paroxysmal AF refractory to antiarrhythmic drugs, 
two patients (A and B, clinical characteristics shown in Table 1) presented LPSVC and absence of 
the right SVC. Underlying structural heart disease had been ruled out through transthoracic 
echocardiography, except for the presence of an unusually dilated CS. Ejection fraction was 
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normal in both patients and left atria (LA) slightly enlarged.  Pre-procedural transesophageal 
echocardiography also ruled out presence of LA thrombus. 
Before the ablation procedure both patients underwent cardiac magnetic resonance (MRI) or 
computed tomography (CT) imaging, which confirmed the presence of a dilated CS due to 
draining of a LPSVC, the absence of the right SVC, and four separate pulmonary veins. Figure 1 
illustrates the 3D-reconstruction of the LPSVC in patient A. 
 
Atrial fibrillation ablation  
After written informed consent was obtained, a decapolar catheter (EzSteer, Biosense-Webster) 
was introduced through the inferior vena cava into the right atria and CS. An 8F circumferential 
decapolar catheter (Lasso, Biosense-Webster) was introduced through the CS towards the LPSVC. 
Electro-anatomic mapping (CARTO, Biosense-Webster) of the right atrium and LPSVC was 
performed by a 4 mm quadripolar catheter (NAVISTAR SF, Biosense-Webster) obtaining a 3-
dimensional voltage map of the right atrium, CS and LPSVC (figure 2A) to merge with the 3D 
MRI/CT scans. Figure 2 illustrates the voltage-map of the right atrium, CS and LPSVC in patient A, 
showing voltages definitely referable to muscular tissue (high amplitude signals, above 1.5 mV) 
in the LPSVC portion adjacent to the LA and at the CS ostium.  
In both patients, at these levels, during sinus rhythm, double potentials were recorded, composed 
by an initial far-field left atrial component followed by a rapid deflection due to the local LPSVC 
or CS potential.  Clear confirmation of this signal interpretation was supported by reversing of 
this sequence during ectopies originating from the muscular portion within the vein (e.g. from 
the LPCVS of patient A in Figure 3). Advancing the circumferential mapping catheter further 
distally into the LPSVC, far from the left atrium far-field and in the normally low voltage vein 
area, obtained instead disappearance of any local potential. 
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In both patients ablation was performed by a 4-mm irrigated-tip catheter (flow-rate 17 mL/min). 
Radiofrequency (RF) was set to temperature control (maximum 45° C) and power limited to 
20W, and performed at the double potential sites presenting muscular voltage values. These 
sites, in both patients, were found within the LPSVC at an upper level, more or less corresponding 
to the left atrial roof, and at a lower level, within the CS towards the connection to the LPSVC 
(Figure 2). Ablation was started by focal radiofrequency at the sites presenting high amplitude 
muscular voltages and double potentials, as those more likely representing the area of LPSVC-CS 
connection, and subsequently the entire LPSVC was isolated to minimize the possibility of 
reconnections (Figure 2, right side: ablation points indicated by red dots).  During ablation, since 
circumflex coronary artery is closely located to the proximal part of the LPSVC, clinical symptoms 
and ECG were carefully monitored. 
Effective disconnection was eventually demonstrated by disappearance of venous potentials on 
the mapping catheter and exit block (pacing 10 mA at 2.0 ms) from the LPSVC and subsequently 
the CS (Figure 3). No acute complications occurred during the procedures and both patients were 
discharged the day following the procedure without antiarrhythmic therapy, while oral 
anticoagulants were continued for 90 days after the ablation. 
Both patients underwent 12-lead electrocardiogram and 24-hour Holter monitoring at 1, 3 and 6 
months after the procedure and every 6 months thereafter. After 14 and 50 months of follow-up, 
respectively, both patients were asymptomatic and in sinus rhythm.  
  
Discussion 
Since the first studies on atrial fibrillation ablation published in 1995 on an animal model,8,9 and 
the first experiences on humans performed by the cardiac surgeons,9,10 atrial fibrillation ablation 
has undergone an impetuous advance achieving, by percutaneous transcatheter approach, 
 7 
satisfactory safety and long-term efficacy results12.  Mimicking the above mentioned experiences, 
extensive linear lesions to modify atrial fibrillation substrate represented the goal of 
transcatheter atrial fibrillation ablation procedures13-16 until the milestone study of Haissaguerre 
et al. in 199817. In this study ectopic foci initiating AF were demonstrated within the pulmonary 
veins. Therefore, the ablation strategy changed from substrate modification by maze-like linear 
lesions in the atria to isolation of the trigger originating from the pulmonary veins, with 
extremely favourable results in both paroxysmal and persistent AF (respectively 15% and 32% 
of recurrences at 10-year follow-up) and very low complications rate (0.8%).18-20 
Other triggers than the pulmonary veins cannot, however, be excluded. In fact, a more aggressive 
trigger elimination approach including pulmonary veins, SVC and CS isolation increased, in single 
experiences, success rates up to 95% after 1 year follow-up.21 More recently, in a study by 
Corrado et al22, systematic SVC isolation significantly improved, from 77% to 90%, the efficacy of 
AF ablation only within patients with paroxysmal AF, confirming the theory that trigger isolation 
alone is mostly effective in paroxysmal AF, while it has limited incremental benefit in case of 
persistent or permanent AF, where remodelling has occurred requiring more extensive substrate 
modification23.  
Given that ectopic activity from the pulmonary veins is the most common AF trigger in 
paroxysmal AF, pulmonary vein isolation surely stands as the primary procedural endpoint for 
patients undergoing transcatheter ablation17. This approach may, however, not be ideal in 
patients, although rare, presenting LPSVC, especially if vein potentials are demonstrated during 
the electrophysiology study24,25. Previous literature has, in fact, proposed LPSVC isolation in 
patients with this venous abnormality, however, in none of the previous experiences pulmonary 
vein isolation was avoided and LPSVC isolation was frequently performed only in case of 
unsuccessful pulmonary vein ablation5,24. The innovative aspect of our work is, indeed, the 
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different approach to this situation. In patients candidate for conventional transcatheter ablation 
of AF, in case the presence of a LPSVC is confirmed, at imaging performed before the procedure, 
and demonstrates to act as an active AF trigger, our opinion is that a limited focal ablation, 
aiming to isolate the LSPVC, should be considered as first choice strategy, leaving PV isolation as 
a second step in case of AF recurrences. 
The evidence of high amplitude voltages referable to muscular tissue, associated to vein 
potentials detected on the mapping catheter, within the LPSVC, should guide ablation and 
provide procedural endpoint (vein isolation).  In both our patients, the firing of the LPSVC was 
demonstrated by the evidence of a reversed activation sequence, as compared to sinus rhythm, 
during ectopies. This is illustrated in Figure 3, panel A, where the electrograms of the 
circumferential catheter (PV 1-10) are shown. During ectopies there is an initial rapid deflection 
due to the local LPSVC activation followed by a far-field left atrial component (Figure 3, black 
arrow). In sinus rhythm, the sequence of the potentials recorded in the same position (within the 
LPSVC) is an initial far-field left atrial component followed by a rapid deflection due to the local 
LPSVC potential (left side of figure 3, panel A). This reversed activation sequence demonstrates 
ectopic beat origin from LPSVC.Interestingly the areas involved within the LPSVC at an upper 
level, more or less corresponding to the left atrial roof, and within the CS towards the connection 
to the LPSVC, have been consistently described ,5,6,24-26 suggesting the possibility to recommend 
the aforementioned approach as a standard ablation protocol. Given the high possibility that 
patients with paroxysmal AF and LPSVC would, in our opinion, not concomitantly present 
triggers from the pulmonary veins, isolation of the sole LPSVC, as here successfully performed in 
two patients, surely holds some advantages. The lesions are limited and, besides avoiding AF 
relapses, the approach we suggest has the relevant potential to avoid unnecessary access to the 
left atrium, reducing consequent well-known transeptal puncture-related risks and embolic 
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complications. In addition, procedure duration, fluoroscopy and ablation time consequently are 
reduced. On the other side, delivering RF within a venous structure, although in areas with 
voltages referable to muscular tissue, requires cautiousness. LPSVC stenosis, to date never 
reported, could indeed be a serious complication being this structure the only outlet for superior 
systemic drainage. In addition, cardiac tamponade, left phrenic nerve paralysis, and circumflex 
coronary artery lesions, due to their anatomical proximity to the mid and distal portion of the 
LPSVC, should carefully be kept in mind24. 
Eventually although a minimum period of 14 months in absence of antiarrhythmic drugs, the 
present follow-up may not permit conclusive results. 
 
Conclusion 
LPSVC is a rare congenital anomaly of the thoracic venous system that can trigger paroxysmal AF. 
The role of this venous anomaly must be carefully considered in patients undergoing 
conventional AF transcatheter ablation by pulmonary vein isolation to avoid unnecessary lesions, 
left atrium access and arrhythmia relapses. In fact, the present clinical perspective suggests that 
sole LPSVC isolation may be a safe and effective approach and, therefore, considered as first 
choice strategy, in patients with paroxysmal AF and arrhythmic trigger originating from a LPSVC.  
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Table 1. Baseline characteristics and procedural outcome. 
 
 Patient A Patient B 
Age 38 50 
Gender M F 
AF type; max duration Paroxysmal; 6 hours Paroxysmal; 10 hours 
AF starting by ectopy yes yes 
CHA2DS2-Vasc 0 1 
Left atrium volume (ml) 86 72 
Ineffective drugs tested propafenone propafenone, amiodarone 
Follow-up (months) 14 50 
Documented recurrences after 
ablation (without AADs) 
none none 
 
AF= atrial fibrillation; AADs= antiarrhythmic drugs
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Figure legends  
1. Cardiac CT three-dimensional reconstruction of the heart of patient A: on the left side a 
posterior view of the heart, showing in blue the inferior vena cava (IVC), the giant coronary 
sinus (CS) and the left persistent superior vena cava (LPSVC); in light blue the posterior 
wall of the left atrium with the pulmonary veins (PV); in yellow the left ventricle (LV) and 
the aorta (Ao); in green the right ventricle with the trunk of pulmonary artery (PA). On the 
right side, an anterior view of the anatomic reconstruction of the right atrium (RA) with the 
giant coronary sinus, the LPSVC, the IVC and the anatomical remnants of the right superior 
vena cava (C).  
2. Voltage-map of the right atrium, CS and LPSVC in patient A based on the electro-anatomic 
mapping system showing voltages definitely referable to muscular tissue (high amplitude 
signals, above 1.50 mV) in the LPSVC portion adjacent to the LA and at the CS.  On the right 
figure, red dots tag, instead, ablation’s sites.  
3.  Panel A: left persistent superior vena cava (LPSVC) potentials recorded during sinus 
rhythm (at the level of the upper line of ablation indicated in Figure 2) with evidence of 
double potential composed by an initial far-field left atrial component followed by a rapid 
deflection due to the local LPSVC. This sequence was reversed during ectopies originating 
from the muscular portion within the vein (black arrow). Panel B: Effective LPSVC isolation, 
demonstrated by disappearance of venous potentials on the mapping catheter (persistence 
of the far-field left atrial component only).  
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Figure 1. 
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Figure 2. 
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Figure 3. 
 
 
 
 
 
